Cargando…
Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD
PURPOSE: Mucolytics can improve disease outcome in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). The objectives of this study were to investigate the effects of erdosteine (ER), a mucolytic agent with antioxidant activity, on systemic inflammation, symptoms, re...
Autores principales: | Moretti, Maurizio, Fagnani, Stefano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630194/ https://www.ncbi.nlm.nih.gov/pubmed/26604731 http://dx.doi.org/10.2147/COPD.S87091 |
Ejemplares similares
-
Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study
por: Dal Negro, Roberto W., et al.
Publicado: (2017) -
Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation
por: Calverley, Peter MA, et al.
Publicado: (2019) -
Effect of Erdosteine on Cyclosporine Induced Chronic Nephrotoxicity
por: Briguori, Carlo, et al.
Publicado: (2012) -
Erdosteine Therapy for Renal Failure: Current Perspectives
por: Muthuraman, Arunachalam
Publicado: (2012) -
Is Acute Exacerbation of COPD (AECOPD) Related to Viral Infection Associated with Subsequent Mortality or Exacerbation Rate?
por: Kherad, Omar, et al.
Publicado: (2014)